Prognostic markers in prostate cancer

Expert Rev Mol Diagn. 2002 Mar;2(2):129-42. doi: 10.1586/14737159.2.2.129.


In this review, a series of relatively well-documented ancillary biomarkers and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and classified as Category I by the College of American Pathologists Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (Category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or clinical trials (Category III).

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Biomarkers, Tumor / analysis
  • Cell Adhesion Molecules / analysis
  • Cell Cycle
  • Growth Substances / analysis
  • Humans
  • Male
  • Neoplasm Staging
  • Neovascularization, Pathologic
  • Oncogenes
  • Prognosis
  • Prostatic Neoplasms / blood supply
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology


  • Biomarkers, Tumor
  • Cell Adhesion Molecules
  • Growth Substances